Clinical trials: Moderate Chronic Obstructive Pulmonary Disease, open to volunteers
COPD (Chronic Obstructive Pulmonary Disease), COPD Exacerbations
The REVIVE Pivotal Study
The goal of this study is to test whether a new treatment called the Ryme Medical Targeted Lung Denervation (TLD) Catheter is safe and effective for people with moderate to severe chronic obstructive pulmonary disease (COPD).
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), COPD Exacerbations, COPD Patients, COPD Acute Exacerbation
- Trial name
- REVIVE (NCT07361653)
- Testing
- Ryme TLD
- Volunteers
- 300 people
- Sponsor
- Ryme Medical, Inc.
Pulmonary Disease, Chronic Obstructive
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with…
- Trial name
- ENDURA-2 (NCT06961214)
- Testing
- Depemokimab
- Where
- 193 sites in United States, Argentina and 14 more
- Volunteers
- 961 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
To evaluate the efficacy of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD)
- Trial name
- NCT07147946
- Testing
- TQC3721 Suspension for inhalation
- Where
- 76 sites in China
- Volunteers
- 666 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pulmonary Disease, Chronic Obstructive
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
The main purpose of this study is to assess if different dose levels of Brenipatide are safe and work the way they are intended to work in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), when…
- Trial name
- RENEW-COPD (NCT07759245)
- Testing
- Brenipatide, Standard of Care
- Where
- 127 sites in United States, Argentina and 16 more
- Volunteers
- 606 people
- Sponsor
- Eli Lilly and Company
Chronic Obstructive Pulmonary Disease
Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
To evaluate the safety of inhaled TQC3721 Suspension in patients with moderate to severe Chronic Obstructive Pulmonary Disease
- Trial name
- NCT07464587
- Testing
- TQC3721 Suspension for Inhalation
- Where
- 54 sites in China
- Volunteers
- 800 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
COPD (Chronic Obstructive Pulmonary Disease)
HFNC Versus NIV in Hypercapneic COPD Patients
Aim: To compare gas exchange trends, clinical outcomes, and tolerability between HFNC and NIV in COPD patients with mild-to-moderate hypercapnic respiratory failure.
- Trial name
- NCT07854210
- Testing
- high flow nasal cannula, non invasive ventilation
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Mohammed Shehta
COPD Exacerbation, Hypercapnia
DUET Versus Standard Interface for Hypercapnic COPD Patients
The goal of this clinical trial is to compare the new asymmetric nasal high flow interface with the conventional high flow nasal cannula in patients with COPD exacerbation.
- Conditions
- COPD Exacerbation, Hypercapnia, COPD
- Trial name
- NCT05829083
- Testing
- Asymmetric nasal cannula - DUET, Conventional nasal high flow cannula
- Where
- 2 sites in Greece
- Volunteers
- 50 people
- Sponsor
- Larissa University Hospital
Chronic Obstructive Lung Disease
A Study to Investigate Small Mobile Stem Cells (SMS) in Moderate to Severe Chronic Obstructive Pulmonary Disease
This study is a phase 1b/2a, open-label, non-randomized, observation of 125 adults, with moderate to severe chronic obstructive pulmonary disease, treated with SORT-COPD (SMS cells).
- Trial name
- SORT-COPD II (NCT07871890)
- Testing
- Stem cells
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- SMSbiotech
Pulmonary Disease, Chronic Obstructive
A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This study is for adult participants with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) who continue to experience exacerbations despite standard of care triple therapy treatment.
- Trial name
- ALARMONY (NCT07915791)
- Testing
- GSK3862995B, GSK5784283
- Volunteers
- 279 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
This study is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to Severe…
- Trial name
- NCT07418736
- Testing
- CM326 dose 1, CM326 dose 2
- Where
- China
- Volunteers
- 318 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Moderate to Severe COPD
Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease
The purpose of this study is to observe the safety and tolerability of Breztri aerosphereTM as maintenance treatment in Indian patients with moderate to severe COPD.
- Trial name
- INDOS-B (NCT06531798)
- Testing
- Breztri Aerosphere
- Where
- 6 sites in India
- Volunteers
- 166 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
This Phase IIb dose-ranging study will evaluate the efficacy and safety of 2 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.
- Trial name
- PRESTO (NCT07082738)
- Testing
- AZD6793
- Where
- 367 sites in United States, Argentina and 22 more
- Volunteers
- 987 people
- Sponsor
- AstraZeneca
Moderate to Severe Chronic Obstructive Pulmonary Disease
A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of Time
A Continuation Study of Tilrekimig in Adults with Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About this Medicine when Used for a Long…
- Trial name
- NCT07839884
- Testing
- Tilrekimig
- Volunteers
- 1,360 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease
A Study of CM512 in Subjects With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase II Study to Explore the Efficacy and Safety of CM512 Injection in Adults with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT06980142
- Testing
- CM512
- Volunteers
- 204 people
- Sponsor
- Keymed Biosciences Co.Ltd
Chronic Obstructive Pulmonary Disease Moderate, Chronic Obstructive Pulmonary Disease Severe
Respiratory and Cardiovascular Alterations in Patients With Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a lung condition characterized by chronic respiratory symptoms (dyspnoea, cough, sputum production and/or exacerbations) due to abnormalities of the airways (e.g.
- Conditions
- Chronic Obstructive Pulmonary Disease Moderate, Chronic Obstructive Pulmonary Disease Severe, Cardiovascular Diseases, Quality of Life
- Trial name
- NCT06072690
- Where
- Lithuania
- Volunteers
- 80 people
- Sponsor
- Lithuanian University of Health Sciences
Chronic Hepatitis B
A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function.
A clinical study evaluating the pharmacokinetic characteristics and safety of AHB-137 injection in participants with mild to moderate liver dysfunction and those with normal liver function.
- Trial name
- NCT07600788
- Testing
- AHB-137 injection
- Where
- 5 sites in China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Ausper Biopharma Co., Ltd.
Chronic Obstructive Airways Disease Exacerbated, Chronic Obstructive Airway Disease
Digital Inhaler Use in Obstructive Lung Disease Care
This is a pilot study to evaluate the role digital inhaler technology on patients with obstructive lung disease in preventing admissions and exacerbation, as well as improving symptom control.
- Trial name
- NCT07214337
- Testing
- Digital Inhaler Attachment
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Pulmonary Disease, Chronic Obstructive (COPD)
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD.
- Trial name
- NCT07039669
- Testing
- 611
- Where
- 4 sites in China
- Volunteers
- 594 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Chronic Obstructive Pulmonary Disease
A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅱ/Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe…
- Trial name
- NCT06547333
- Testing
- CM310
- Volunteers
- 884 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Chronic Obstructive Pulmonary Disease (COPD)
HIIT Versus MICT in COPD: Effects on Oxygenation, Pulmonary Function, and Strength
Chronic Obstructive Pulmonary Disease (COPD) is a progressive condition marked by airflow limitation and chronic inflammation, leading to reduced exercise capacity, peripheral muscle dysfunction, and dyspnea.
- Trial name
- NCT07109687
- Testing
- HIIT GROUP, MICT
- Volunteers
- 40 people
- Sponsor
- Aynur Demirel